Rezdiffra Data Shows Reduced Cardiovascular, Liver Risk in MASH Patients
MDGL sits 98% above its 52-week low of $265.
Summary
Madrigal Pharmaceuticals presented new Phase 3 and real-world data at the EASL Congress, demonstrating Rezdiffra's ability to reduce markers of cardiovascular and liver-related risk in MASH patients. The data showed improvements in key atherogenic lipids like LDL-C and Lp(a), and progressive improvements in risk scores for clinically significant portal hypertension in compensated MASH cirrhosis, a population currently lacking approved therapies. This positive data reinforces Rezdiffra's market position and expands its potential benefits beyond liver histology, addressing significant comorbidities and strengthening its long-term sales outlook. This follows the strong Q1 Rezdiffra sales reported earlier this month.
At the time of this announcement, MDGL was trading at $524.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $265.00 to $615.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.